Press release - 20/07/2023 Animal testing under REACH: bringing numbers into the debate So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tierversuche-durch-reach-zahlen-die-debatte-bringen
Dossier - 09/02/2015 Chemical tools for biological applications The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology. https://www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
Press release - 05/09/2024 Cohesion at the cellular level: flexible yet stable Research teams from the Universities of Konstanz and Potsdam are analyzing how proteins work together to enable our cells to both stick and move. The marker protein paxillin is at the centre of their interest.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cohesion-cellular-level-flexible-yet-stable
All-enzyme hydrogels in action - 13/12/2023 Biocatalytic foams enable the sustainable synthesis of complex molecules Conventional chemical synthesis processes consume large amounts of energy and environmentally harmful solvents. Prof. Dr. Christof Niemeyer’s team at the Karlsruhe Institute of Technology has generated porous, solid foams from crosslinked enzymes that allow the production of high-quality compounds under significantly more environmentally friendly conditions. The novel biocatalysts are also extremely resistant and have a long shelf life.https://www.gesundheitsindustrie-bw.de/en/article/news/biocatalytic-foams-enable-sustainable-synthesis-complex-molecules
Press release - 24/04/2023 Hidden RNA repair mechanism discovered in humans Konstanz researchers discover the function of a previously unexplored protein: In three characteristic steps, "C12orf29" links the ends of RNA strands. Proteins that perform this kind of RNA ligation were previously unknown in humans. The results of the study suggest that it is important for RNA repair during cellular stress.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hidden-rna-repair-mechanism-discovered-humans
Press release - 28/01/2022 Artificial Muscles Made of Proteins Dr. Stefan Schiller and Dr. Matthias Huber from the University of Freiburg’s livMatS Cluster of Excellence have succeeded in developing a muscle solely on the basis of natural proteins. The autonomous contractions of the material, which the researchers presented in the journal Advanced Intelligent Systems, can be controlled with the help of pH and temperature changes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-muscles-made-proteins
Microstructure Technology - 17/07/2020 An electronic nose for many applications Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
Dossier - 17/01/2017 Phytopharmaceuticals – fighting disease with natural substances Phytopharmaceuticals are herbal medicines whose efficacy is down to one or several plant substances or active ingredients. They have been used for treating diseases since time immemorial. This traditional knowledge is still the basis for many medicinal products made from plants or parts thereof. Herbal medicines have been produced in Baden-Württemberg for many generations.https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances
Press release - 29/11/2022 Prototype funding for two Konstanz projects Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".https://www.gesundheitsindustrie-bw.de/en/article/press-release/doppelter-erfolg-der-prototypenfoerderung
Organ failure due to fatty liver - 24/09/2020 HepaRegeniX develops an active substance for liver regeneration When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure. https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
Press release - 18/12/2023 Researchers discover novel antibiotic substance from the human nose For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose
Press release - 01/10/2024 Reporter Skin: In-vitro Skin Makes Cell Reaction to Test Substance Measurable in Real Time At the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, a three-dimensional skin model has now been set up for the first time that directly displays the skin's reaction to substances: The reporter skin. Thanks to the built-in reporter, the cellular response can be measured precisely and quickly – using a living model. https://www.gesundheitsindustrie-bw.de/en/article/press-release/reporter-skin-vitro-skin-makes-cell-reaction-test-substance-measurable-real-time
Press release - 10/02/2022 CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-participant-phase-1-study-multivalent-influenza-vaccine-candidate-based-second-generation-mrna-backbone-deve
Press release - 14/03/2024 Planned NMI spin-off: immuneAdvice successful in start-up competition Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/geplante-nmi-ausgruendung-immuneadvice-bei-startup-wettbewerb-erfolgreich
Press release - 13/06/2024 Eyesight from a 3D Printer Printing a new cornea during an operation to restore a patient’s eyesight: This groundbreaking step in the fight against corneal disorders is set to become reality with a laser based process using personalized bioink. The method was developed by researchers at the Karlsruhe Institute of Technology (KIT) in collaboration with Carl Zeiss Meditec AG and Evonik Healthcare. Their project won the idea award in this year’s NEULAND innovation contest.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eyesight-3d-printer
Press release - 17/01/2023 Sugar-based inhibitors disarm the pathogen Pseudomonas aeruginosa The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zuckerbasierte-inhibitoren-entwaffnen-den-krankheitserreger-pseudomonas-aeruginosa
Press release - 30/11/2023 Taking antibiotics back in time University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/taking-antibiotics-back-time
Article - 17/03/2021 Epigenetic switches in bacteria as biosensors The analysis of pathogen biomarkers and biomarkers for the diagnosis of diseases can be crucial for health. However, the detection of pathogens and diseases depends on a sensitive and reliable method that delivers rapid results. Biosensors have such properties. Researchers at the Institute of Biochemistry and Technical Biochemistry (IBTB) at Stuttgart University have constructed an epigenetic circuit composed of plasmids that might make it…https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetic-switches-bacteria-biosensors
Press release - 03/09/2024 NMR Spectroscopy: A Faster Way to Determine the “Sense of Rotation” of Molecules Researchers of Karlsruhe Institute of Technology (KIT) and Voxalytic GmbH developed a new method that allows, for the first time, to elucidate the chiral structure of molecules – the exact spatial arrangement of the atoms – by nuclear magnetic resonance (NMR) spectroscopy. This important step in the development of new drugs used to be a time-consuming process until now. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmr-spectroscopy-faster-way-determine-sense-rotation-molecules
Press release - 14/11/2022 Neurotoxicological hazard assessment without animal testing Using animal-free methods to assess the hazard potential of chemicals to the nervous system of unborn children? An international research team including toxicologists from Konstanz and Düsseldorf has developed a testing battery based on human cells that has the potential to replace traditional methods for assessing developmental neurotoxicity.https://www.gesundheitsindustrie-bw.de/en/article/press-release/neurotoxicological-hazard-assessment-without-animal-testing
Press release - 30/03/2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
Company profile - 09/01/2019 HQS Quantum Simulations for industrial quantum mechanics applications The door to the quantum world is opening wider and wider. Behind it is a whole new view of materials and molecules. Quantum mechanics applications not only benefit science, they also offer huge economic potential. The Karlsruhe start-up HQS Quantum Simulations is playing a pioneering role in quantum simulations for the chemical and pharmaceutical industries.https://www.gesundheitsindustrie-bw.de/en/article/news/hqs-quantum-simulations-for-industrial-quantum-mechanics-applications
Press release - 01/02/2021 Targeting a rapid market breakthrough for new vaccine production method In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method